Patient P-02445
Synthetic patientMETA-24 · Day 158 · 45–54 · F · baseline S09Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
79%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S09
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 68 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 80 GI-04 recommended — GI Support Protocol GI-04
- Day 81 Patient accepted — Started GI-04 in the companion
- Day 89 GI symptom burden −30% vs expected — GI Support Protocol GI-04
- Day 95 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 68.
Primary contributors, last 14 days
- GI instability+14
- Inflammatory activity+12
- Nutritional resilience-12
- Toxicity+5
- Treatment adherence-2
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 80Result: symptom burden −30%
LIFE OS recommendation
Monitoring Escalation ME-01
91%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable13 min
worsening · -5.0 vs previous 14 d
Sleep duration
Wearable5.3 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log1.5/10
worsening · -0.9 vs previous 14 d
Steps
Wearable2,296
worsening · -545 vs previous 14 d
GI burden
Companion63.8/100
worsening · +10.8 vs previous 14 d
Adherence
Companion54.9 %
stable · +1.6 vs previous 14 d
Sleep quality
Wearable14.4/100
worsening · -6.2 vs previous 14 d
Glucose, CGM daily mean
CGM148 mg/dL
stable · +2.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 23 from the failing basin, 68 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 42 similar · onset 3 d · confidence 79%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 79%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 79%
- More proteinGI -2.9 next day on high-intake days · n 20
Would not help
- NP-02 Dietary Support Protocolalready tried, no meaningful change
- Keep fat lowGI +3.1 next day on high-intake days · n 24
- Keep fibre lowGI +2.6 next day on high-intake days · n 18
- Keep histamine lowGI +2.4 next day on high-intake days · n 17
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+3.1detractor · 95%
- Protein-2.9supporter · 95%
- Insoluble fibre+2.6detractor · 95%
- Histamine load+2.4detractor · 79%
- Ultra-processed food+1.2no signal · 36%
- Simple carbohydrates-0.9no signal · 33%
- Alcohol+0.3no signal · 15%
- Caffeine-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
- WearableHRV 17 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 75 bpm
- Wearable2,296 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 64 and rising
- WearableSleep 5.3 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 27/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 27/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 21 ms
- Sleep
- 5.3 h
- Steps
- 2,427
- Resting HR
- 75 bpm
Daily log: GI score 64, nutritional resilience 35, adherence 55.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02552 | 21% | S07 | AD-05 | no change | 29 |
| P-02093 | 20% | S05 | AD-05 | no change | 40 |
| P-02483 | 22% | S06 | BR-03 | no change | 64 |
| P-02564 | 21% | S15 | BR-03 | improved | 32 |
| P-02087 | 20% | S01 | BR-03 | no change | 40 |
| P-02308 | 20% | S13 | BR-03 | no change | 27 |
| P-02151 | 34% | S04 | CR-01 | improved | 49 |
| P-02054 | 31% | S01 | CR-01 | improved | 57 |
| P-02009 | 30% | S08 | CR-01 | improved | 64 |
| P-02025 | 30% | S15 | CR-01 | improved | 61 |
| P-02154 | 28% | S16 | CR-01 | improved | 57 |
| P-02233 | 27% | S16 | CR-01 | improved | 66 |